GLP-1 Receptor Agonists Consistently Reduce Hepatic Fat in NAFLD/MASLD, Showing Steatohepatitis Resolution
Background
Non-alcoholic fatty liver disease (NAFLD), now termed metabolic dysfunction-associated steatotic liver disease (MASLD), is a rapidly increasing cause of chronic liver disease, often progressing to metabolic dysfunction-associated steatohepatitis (MASH). Current treatment options are limited, creating a significant unmet medical need. Glucagon-like peptide-1 (GLP-1) receptor agonists (GLP-1RAs), already approved for type 2 diabetes and obesity, exert broad metabolic benefits that suggest potential for addressing the underlying pathophysiology of MASLD and MASH.
Study Design
This systematic review evaluated the therapeutic effects of GLP-1 receptor agonists in adults diagnosed with NAFLD, NASH, MASLD, or MASH. Researchers systematically searched PubMed, Scopus, Embase, and the Cochrane Library using keywords related to both NAFLD and GLP-1 receptor agonists. Twelve studies met the inclusion criteria. Due to significant heterogeneity in study populations, designs, and reported outcomes, findings were synthesized narratively rather than through a meta-analysis. The review is registered with PROSPERO (CRD420261337353).
Results
The most consistent and robust finding across the included studies was a significant reduction in hepatic fat. This benefit was observed with several GLP-1 receptor agonists, including semaglutide, liraglutide, dulaglutide, and beinaglutide. Improvements in liver enzymes, particularly alanine aminotransferase (ALT), were less consistent and considered supportive rather than definitive evidence of histological improvement. Histological benefits were strongest for steatohepatitis resolution, particularly in non-cirrhotic MASH patients. Fibrosis outcomes were mixed; the greatest benefit was noted in F2-F3 MASH, while established cirrhosis showed limited improvement. GLP-1 receptor agonists were generally well tolerated, with gastrointestinal symptoms being the most common adverse effects.
The most consistent outcome was a reduction in hepatic fat, seen with semaglutide, liraglutide, dulaglutide, and beinaglutide.
Key Findings
- GLP-1 receptor agonists consistently reduced hepatic fat across multiple studies.
- Steatohepatitis resolution was a strong histological benefit, particularly in non-cirrhotic MASH.
- Liver enzyme improvements (e.g., ALT) were less consistent but supportive.
- Fibrosis benefits were most evident in F2-F3 MASH, with limited improvement in cirrhosis.
- GLP-1 receptor agonists were generally well tolerated, with common GI side effects.
Why It Matters
This systematic review reinforces the growing evidence that GLP-1 receptor agonists represent a promising therapeutic avenue for MASLD and MASH, especially for individuals with co-existing obesity or type 2 diabetes, or those in earlier stages of liver disease. For peptide users and clinicians, this suggests that GLP-1RAs like semaglutide or liraglutide could be integrated into treatment protocols for liver health, beyond their established roles in metabolic control. However, their impact on advanced fibrosis and long-term clinical outcomes remains less clear, indicating that while current data is encouraging, larger, longer-term studies are essential to fully define their role and optimal protocols in advanced liver disease.
glp-1-agonist
nafld
masld
nash
mash
hepatic-fat